Log in to save to my catalogue

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis...

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1614079789

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial

About this item

Full title

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial

Publisher

London: Lancet Publishing Group

Journal title

The Lancet infectious diseases, 2014-11, Vol.14 (11), p.1055-1064

Language

English

Formats

Publication information

Publisher

London: Lancet Publishing Group

More information

Scope and Contents

Contents

Summary Background Antiretroviral pre-exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtricitabine, has been shown to be efficacious for HIV-1 prevention. Although the use of more than one antiretroviral agent is essential for effective HIV-1 treatment, more than one a...

Alternative Titles

Full title

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1614079789

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1614079789

Other Identifiers

ISSN

1473-3099

E-ISSN

1474-4457

DOI

10.1016/S1473-3099(14)70937-5

How to access this item